{"id":15957,"date":"2022-03-08T12:04:53","date_gmt":"2022-03-08T11:04:53","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15957"},"modified":"2022-03-08T12:04:53","modified_gmt":"2022-03-08T11:04:53","slug":"remboursement-dultomiris-ravulizumab-pour-le-traitement-des-adultes-atteints-dhemoglobinurie-paroxystique-nocturne-hpn","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/remboursement-dultomiris-ravulizumab-pour-le-traitement-des-adultes-atteints-dhemoglobinurie-paroxystique-nocturne-hpn\/","title":{"rendered":"Remboursement d\u2019Ultomiris\u00ae (ravulizumab) pour le traitement des adultes  atteints d\u2019H\u00e9moglobinurie Paroxystique Nocturne (HPN)"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1240px + 0px );margin-left: calc(-0px \/ 2 );margin-right: calc(-0px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:0px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:0px;--awb-width-medium:100%;--awb-spacing-right-medium:0px;--awb-spacing-left-medium:0px;--awb-width-small:100%;--awb-spacing-right-small:0px;--awb-spacing-left-small:0px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>Alexion Pharma France a annonc\u00e9 le 8 mars 2022 la publication au Journal Officiel (JO) de l\u2019agr\u00e9ment aux collectivit\u00e9s et de l\u2019inscription sur la liste en sus de la T2A de sa sp\u00e9cialit\u00e9, Ultomiris (ravulizumab), solution \u00e0 diluer pour perfusion (en pr\u00e9sentations de 1100mg\/11 ml et 300 mg\/3ml), dans le traitement de l\u2019H\u00e9moglobinurie Paroxystique Nocturne (HPN) chez les patients adultes qui pr\u00e9sentent une h\u00e9molyse avec un ou des sympt\u00f4me(s) clinique(s) indiquant une forte activit\u00e9 de la maladie ou qui sont stables sur le plan clinique apr\u00e8s un traitement par l\u2019eculizumab pendant au moins les six derniers mois.<\/p>\n<p>\u00ab La disponibilit\u00e9 d\u2019Ultomiris repr\u00e9sente une avanc\u00e9e majeure pour le traitement des patients atteints d\u2019HPN \u00bb a d\u00e9clar\u00e9 le professeur R\u00e9gis Peffault de Latour, h\u00e9matologue \u00e0 l&#8217;h\u00f4pital Saint-Louis \u00e0 Paris (AP-HP) et coordinateur du centre de r\u00e9f\u00e9rence des aplasies m\u00e9dullaires acquises et constitutionnelles. \u00ab Les patients fran\u00e7ais souffrant d\u2019HPN ont d\u00e9sormais plus de libert\u00e9 gr\u00e2ce \u00e0 ce traitement administr\u00e9 \u00e0 une fr\u00e9quence r\u00e9duite avec une efficacit\u00e9 et un profil de tol\u00e9rance similaires \u00e0 celui d\u2019eculizumab. \u00bb.<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[457],"class_list":["post-15957","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-pascale-raoul"],"aioseo_notices":[],"authors":[{"term_id":457,"user_id":17,"is_guest":0,"slug":"pascale-raoul","display_name":"Pascale Raoul","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","first_name":"","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15957"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15957\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15957"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}